TVU Networks Celebrates 20 Years of Innovation at NAB 2025
Company to Showcase AI Offerings and Expanded Cloud Ecosystem. CUPERTINO, Calif., March 13, 2025 /PRNewswire/ -- TVU Networks, a pioneer in live video production and a leader in cloud-based media solutions, is marking its 20th anniversary at NAB...
Ping An Health Reports First Full-Year Profit in 2024
Synergies Between Health Care and Insurance Drive Scalable Growth AI Innovations Fuel Continued Success SHANGHAI and HONG KONG, March 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health"...
Hanwha Aerospace Receives DNV AIP Certification on Hydrogen Fuel Cells
Global Authority DNV Validates Top-Tier Safety and Performance Standards Second Major Certification Following Korean Register Approval Last Year Company Positioned to Advance Zero-Carbon Maritime Propulsion Technology SEOUL, South Korea, March 13,...
Copute Partners The Ignition AI Accelerator, a Collaboration Among NVIDIA, Tribe, and DISG, Drive Innovations in Decentralised AI
SINGAPORE, March 13, 2025 /PRNewswire/ -- The Ignition AI Accelerator, a collaboration between NVIDIA, Tribe, and Digital Industry Singapore (DISG), announces its partnership with Copute, a pioneering Web3 ecosystem dedicated to decentralised...
Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma Manufacturing and Quality
PITTSBURGH, March 13, 2025 /PRNewswire/ -- Caliber recently launched 4 digital solutions that further strengthen its portfolio and also position the company at the forefront of the Pharma 4.0 revolution. These innovations integrate AI and next-gen...
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
STEQEYMA ® , one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the...
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea, March 13, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This...
Armor Collaborates with Oracle to Help Organizations Protect Their Critical Workloads
DALLAS, March 13, 2025 /PRNewswire/ -- Armor, a leading provider of cybersecurity and compliance solutions, today announced it has joined the Oracle Partner Program. As an Oracle partner, Armor will collaborate with Oracle to provide organizations...